Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI)
| Registry | NCT02460354 |
|---|---|
| Status | Terminated - Lack of effect in initial subjects |
| Phase | Phase 1 |
| Study type | Interventional; na, single group, masking: none, treatment |
| Enrollment | 2 (Actual) |
| Sponsor | Emory University (Other) |
| Conditions | Diabetes Insipidus |
| Interventions | Metformin (Drug) |
| Dates | start 2015-09-01, primary completion 2017-06-01, completion 2017-06-01, first posted 2015-06-02, last updated 2018-07-17 |
| Locations | 3 sites in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Diabetes Insipidus All trials of Metformin
The purpose of this study is to determine whether metformin can increase urine concentration (osmolality) and decrease the amount of urine in patients with congenital nephrogenic diabetes insipidus (NDI).
Nephrogenic diabetes insipidus (NDI) is a genetic disease. Patients with this disease make large amounts of urine because their kidneys don't hold on to water. The large amount of urine means that patients need to urinate very frequently. They are also at increased risk for dehydration if they don't drink enough. The large amount of urine can sometimes damage their bladders and kidneys. There are some medicines that may help these patients urinate less, but they are not very effective. There is evidence in animal studies that a medication called metformin may help patients with NDI urinate less.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Metformin | Experimental | Drug: Metformin | Subjects with congenital nephrogenic diabetes insipidus (NDI) will receive one metformin 500 mg pill orally |
Sex: Male, ages: 18 Years to any
Inclusion Criteria: * Males with a documented mutation in the vasopressin type 2 receptor (V2R) * Willing to provide consent and/or assent as appropriate * Capable of providing urine samples as dictated by the protocol Exclusion Criteria: * Urinary incontinence * Subjects who have heart disease, liver disease, diabetes, cancer, or other significant disease other than Nephrogenic Diabetes Insipidus (NDI) * Subjects with significant renal dysfunction (defined as a calculated glomerular filtration rate (GFR) <80 ml/min/1.73 m\^2) * Subjects with acquired NDI
| Facility | City | Country | Status |
|---|---|---|---|
| Childen's Healthcare of Atlanta | Atlanta, Georgia | United States | |
| Emory University Hospital - Atlanta Clinical and Translational Science Institute (ACTSI) | Atlanta, Georgia | United States | |
| Emory University Hospital | Atlanta, Georgia | United States |